Immunotherapy plus chemo shows promise for tough uterine cancer

NCT ID NCT06561308

Recruiting now Disease control Sponsor: Women's Hospital School Of Medicine Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study is testing whether adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery can help shrink advanced endometrial cancer. About 39 women with stage III or IV disease will receive the combination, then undergo surgery. The main goal is to see how many have no cancer cells left in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Camrelizumab (a PD-1 inhibitor) combined with carboplatin and paclitaxel chemotherapy
What this could lead to: If successful, this combination could become a new standard approach to shrink advanced endometrial tumors before surgery, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 39 participants, so results may not apply broadly. The added immunotherapy also carries risks of immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial endometrioid adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOID ENDOMETRIAL CANCER

Contacts and locations

Locations

Women's hospital school of medicine zhejiang university
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.